Get the Stockscreener App
1.54
1.91%
-0.03
After Hours:
1.58
0.04
+2.60%
Intercure Ltd stock is traded at $1.54, with a volume of 181.83K.
It is down -1.91% in the last 24 hours and down -0.65% over the past month.
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
See More
Previous Close:
$1.57
Open:
$1.54
24h Volume:
181.83K
Relative Volume:
9.97
Market Cap:
$85.58M
Revenue:
$118.18M
Net Income/Loss:
$5.99M
P/E Ratio:
11.68
EPS:
0.1319
Net Cash Flow:
$-12.91M
1W Performance:
+2.67%
1M Performance:
-0.65%
6M Performance:
-10.79%
1Y Performance:
-41.22%
1-Day Range:
$1.48
$1.5734
1-Week Range:
$1.48
$1.59
52-Week Range:
$1.17
$2.53
Intercure Ltd Stock (INCR) Company Profile
Compare INCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCR
Intercure Ltd
|
1.54 | 85.58M | 118.18M | 5.99M | -12.91M | 0.1319 |
|
ZTS
Zoetis Inc
|
153.45 | 67.31B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 45.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.75 | 43.35B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.58 | 18.68B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
305.61 | 13.44B | 2.99B | 1.21B | 1.13B | 25.06 |
Intercure Ltd Stock (INCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-22 | Upgrade | Canaccord Genuity | Speculative Buy → Buy |
Intercure Ltd Stock (INCR) Latest News
Is InterCure Ltd. a good long term investmentDynamic profit expansion - Autocar Professional
InterCure Ltd. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional
What analysts say about InterCure Ltd. stockHigh-velocity capital appreciation - jammulinksnews.com
What drives InterCure Ltd. stock priceExceptional return forecasts - jammulinksnews.com
How InterCure Ltd. stock performs during market volatilityFree Stock Selection with 300% Return - Newser
InterCure (NASDAQ:INCR) Shares Down 3.5% – Here’s What Happened - Defense World
What makes InterCure Ltd. stock price move sharply2x Return Forecast - newser.com
Why InterCure Ltd. stock attracts strong analyst attentionSmart Money Signals - Newser
InterCure (NASDAQ:INCR) Stock Price Up 1.9% – What’s Next? - Defense World
InterCure And Cookies Successfully Launch Flagship Pharmacy In Be'er Sheva, Israel - Barchart.com
InterCure (NASDAQ:INCR) Shares Down 4.4% – What’s Next? - Defense World
InterCure Reports FY2024 Results - mg Magazine
InterCure Reports Strong Start to 2025 Amid Recovery Efforts - TipRanks
InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PR Newswire
Intercure Ltd. Delays Yearly Report Filing - TipRanks
Interbusiness, Virdis partner to distribute Intercure products - Rubber News
InterCure (NASDAQ:INCR) Stock Price Down 3.4% – Time to Sell? - Defense World
InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - GuruFocus.com
InterCure (NASDAQ:INCR) Shares Down 0.7%What's Next? - MarketBeat
InterCure Announces Leadership Change and Secures $18.2 Million Financing - TipRanks
Short Interest in InterCure Ltd. (NASDAQ:INCR) Expands By 96.2% - MarketBeat
Jane Street Group LLC Acquires New Stake in InterCure Ltd. (NASDAQ:INCR) - Defense World
InterCure (NASDAQ:INCR) Trading Up 3.7% – Should You Buy? - Defense World
Cannabis co InterCure raising NIS 66m for Nir Oz facilityGlobes - Globes - Israel Business News
InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PR Newswire
Synbiotic's CAGR Forecast at 80%, ECS Botanics to Expand Footprint in Germany, & More from Intercure - Business of Cannabis
Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
InterCure nears break even in first half of 2024, despite ongoing Israel-Hamas war - Crain's Chicago Business
InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewswire
InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Yahoo Finance
IM Cannabis Merger Scrapped, Cel AI Gets a New CEO, & More from Intercure - Business of Cannabis
Analyst: Israel’s InterCure paving path to big gains - Green Market Report
InterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis Conference - Business Wire
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million - Business Wire
InterCure: Bargain Israel Cannabis Play (NASDAQ:INCR) - Seeking Alpha
Intercure Ltd Stock (INCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):